Quick Answer
Galera Therapeutics, Inc. reported Cash and Equivalents of $6.38 million for fiscal year 2025.
Galera Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.38M | -23.1% |
| 2024 | $8.29M | -54.6% |
| 2023 | $18.26M | +328.0% |
| 2022 | $4.27M | -78.5% |
| 2021 | $19.86M | +25.1% |
| 2020 | $15.87M | -13.5% |
| 2019 | $18.36M | +23.9% |
| 2018 | $14.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.47M | -47.1% | -14.5% |
| June 30, 2025 | $5.23M | -51.3% | -21.8% |
| March 31, 2025 | $6.69M | -50.3% | -19.3% |
| December 31, 2024 | $8.29M | -54.6% | -2.0% |
| September 30, 2024 | $8.46M | -65.3% | -21.3% |
| June 30, 2024 | $10.75M | -55.8% | -20.2% |
| March 31, 2024 | $13.47M | -47.6% | -26.2% |
| December 31, 2023 | $18.26M | +328.0% | -25.1% |
- Galera Therapeutics, Inc. showed a decrease of -23.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Galera Therapeutics, Inc.’s cash and equivalents has declined by 57.0% (from $14.81 million to $6.38 million).
- The most recent figure is from Galera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: